66.43
price up icon1.71%   1.12
after-market Handel nachbörslich: 66.43
loading
Schlusskurs vom Vortag:
$65.31
Offen:
$65.15
24-Stunden-Volumen:
646.90K
Relative Volume:
1.56
Marktkapitalisierung:
$3.27B
Einnahmen:
$1.11B
Nettoeinkommen (Verlust:
$205.95M
KGV:
16.16
EPS:
4.11
Netto-Cashflow:
$254.64M
1W Leistung:
-11.62%
1M Leistung:
-13.16%
6M Leistung:
-22.47%
1J Leistung:
-1.26%
1-Tages-Spanne:
Value
$65.15
$66.57
1-Wochen-Bereich:
Value
$62.95
$72.89
52-Wochen-Spanne:
Value
$62.95
$90.04

Prestige Consumer Healthcare Inc Stock (PBH) Company Profile

Name
Firmenname
Prestige Consumer Healthcare Inc
Name
Telefon
(914) 524-6800
Name
Adresse
660 WHITE PLAINS RD., TARRYTOWN, NY
Name
Mitarbeiter
600
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
PBH's Discussions on Twitter

Vergleichen Sie PBH mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
PBH
Prestige Consumer Healthcare Inc
66.43 3.14B 1.11B 205.95M 254.64M 4.11
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
152.44 66.38B 9.39B 2.61B 2.22B 5.81
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.77 46.20B 29.98B 958.27M 5.31B 0.2964
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.69 42.99B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
17.21 18.84B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
309.72 13.59B 2.99B 1.21B 1.13B 25.06

Prestige Consumer Healthcare Inc Stock (PBH) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-09 Herabstufung Sidoti Buy → Neutral
2024-06-21 Hochstufung DA Davidson Neutral → Buy
2022-11-17 Eingeleitet Canaccord Genuity Buy
2022-05-10 Hochstufung Jefferies Hold → Buy
2022-05-09 Hochstufung Oppenheimer Perform → Outperform
2020-08-07 Herabstufung DA Davidson Buy → Neutral
2020-06-29 Hochstufung Sidoti Neutral → Buy
2020-04-14 Herabstufung Jefferies Buy → Hold
2020-04-07 Fortgesetzt Sidoti Neutral
2020-03-26 Hochstufung Jefferies Hold → Buy
2020-03-24 Eingeleitet Oppenheimer Perform
2020-03-19 Hochstufung DA Davidson Neutral → Buy
2019-01-15 Herabstufung Raymond James Outperform → Mkt Perform
2017-12-04 Hochstufung William Blair Mkt Perform → Outperform
2017-06-02 Hochstufung Jefferies Underperform → Hold
2017-05-22 Hochstufung Raymond James Mkt Perform → Outperform
2016-12-27 Bestätigt B. Riley & Co. Buy
2016-11-17 Eingeleitet Gabelli & Co Buy
2016-08-12 Hochstufung Sidoti Neutral → Buy
2016-03-08 Eingeleitet KeyBanc Capital Mkts Overweight
2016-02-05 Eingeleitet Piper Jaffray Overweight
2015-11-30 Herabstufung Jefferies Hold → Underperform
2014-04-28 Bestätigt B. Riley & Co. Buy
2014-04-28 Bestätigt Oppenheimer Outperform
2013-07-09 Eingeleitet B. Riley & Co. Buy
Alle ansehen

Prestige Consumer Healthcare Inc Aktie (PBH) Neueste Nachrichten

pulisher
05:52 AM

Prestige Consumer Healthcare (PBH) Trims Outlook as Sales Dip—Is the Acquisition Strategy Still on Track? - simplywall.st

05:52 AM
pulisher
Aug 10, 2025

Prestige Consumer Healthcare's Strategic Acquisition and Q1 Earnings: A Value Investment Case in a Resilient OTC Sector - AInvest

Aug 10, 2025
pulisher
Aug 10, 2025

Prestige Consumer Healthcare Inc. (NYSE:PBH) Just Released Its First-Quarter Earnings: Here's What Analysts Think - Yahoo Finance

Aug 10, 2025
pulisher
Aug 09, 2025

Prestige Consumer Healthcare Acquires Pillar5 Pharma for Expansion - MSN

Aug 09, 2025
pulisher
Aug 09, 2025

Prestige Consumer Healthcare Inc. (NYSE:PBH) Q1 2026 Earnings Call Transcript - Insider Monkey

Aug 09, 2025
pulisher
Aug 08, 2025

Prestige Consumer Starting Clear Eyes Production With No Contract Partner ‘Out There To Tap Into’ - insights.citeline.com

Aug 08, 2025
pulisher
Aug 08, 2025

Prestige Consumer Healthcare's Q1 2026: Key Contradictions in Clear Eyes Supply, Market Share, and Margin Outlook - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

Prestige Consumer Healthcare stock hits 52-week low at 64.83 USD By Investing.com - Investing.com South Africa

Aug 08, 2025
pulisher
Aug 08, 2025

Prestige Consumer Healthcare stock hits 52-week low at 64.83 USD - Investing.com Nigeria

Aug 08, 2025
pulisher
Aug 08, 2025

Prestige Brands stock price target lowered to $100 at Canaccord on eye care supply issues - Investing.com Nigeria

Aug 08, 2025
pulisher
Aug 08, 2025

Prestige Consumer Healthcare's Strategic Path to Recovery: Can Shareholders Capitalize on a Turnaround in Eye Care and Margin Expansion? - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

Prestige Consumer Healthcare: Fiscal Q1 Earnings Snapshot - Manistee News Advocate

Aug 08, 2025
pulisher
Aug 08, 2025

Prestige Consumer Healthcare: Strategic Acquisitions and Innovation Drive Long-Term Value Creation - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

Prestige Consumer Healthcare outlines $1.1B-$1.115B FY26 revenue target amid Pillar5 acquisition and Clear Eyes supply recovery - MSN

Aug 08, 2025
pulisher
Aug 08, 2025

Prestige Consumer Healthcare Q1 Earnings and Strategic Acquisition of Pillar5 Pharma - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

Prestige Consumer Healthcare’s Q1 Earnings and Strategic Moves - TipRanks

Aug 08, 2025
pulisher
Aug 07, 2025

Prestige Consumer Healthcare Q1 2026 Earnings Call Transcript - MarketBeat

Aug 07, 2025
pulisher
Aug 07, 2025

Prestige Consumer Healthcare shares fall 10.14% intraday after missing Q1 revenue estimates and lowering fiscal 2026 outlook. - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Prestige Consumer Healthcare Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 07, 2025
pulisher
Aug 07, 2025

Prestige Consumer Healthcare Inc. Q1 Profit Decreases, Misses Estimates - Nasdaq

Aug 07, 2025
pulisher
Aug 07, 2025

Prestige Consumer Healthcare (PBH) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance

Aug 07, 2025
pulisher
Aug 07, 2025

Prestige Consumer Healthcare's Strategic Acquisition of Anjac SAS: A Catalyst for OTC Men's Health Dominance - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Prestige Consumer Healthcare Eyes Growth Despite Revenue Shortfall - Finimize

Aug 07, 2025
pulisher
Aug 07, 2025

Prestige Consumer Healthcare on Aug 4, unit entered agreement with Anjac SASSEC filing - MarketScreener

Aug 07, 2025
pulisher
Aug 07, 2025

Prestige Consumer Healthcare Q1 FY26 slides: Revenue drops on supply issues, margins improve - Investing.com Nigeria

Aug 07, 2025
pulisher
Aug 07, 2025

Prestige Consumer Healthcare Q1 FY26 slides: Revenue drops on supply issues, margins improve By Investing.com - Investing.com South Africa

Aug 07, 2025
pulisher
Aug 07, 2025

Prestige Consumer Healthcare (PBH) Misses Q1 Earnings and Revenue Estimates - Yahoo Finance

Aug 07, 2025
pulisher
Aug 07, 2025

Prestige Consumer Healthcare Q1 Revenue Falls 6.6% Amid Supply Constraints and Order Timing Shifts - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Prestige Consumer Healthcare's Strategic Acquisition of Pillar5 Pharma: A Masterstroke in Supply Chain Resilience and Competitive Edge - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Prestige Consumer Healthcare Reports Lower Q1 Earnings Than ExpectedNews and Statistics - IndexBox

Aug 07, 2025
pulisher
Aug 07, 2025

Prestige (PBH) Q1 Revenue Falls 6.6% - The Globe and Mail

Aug 07, 2025
pulisher
Aug 07, 2025

Prestige Consumer's Strategic Turnaround: Assessing Brand Resilience and M&A-Driven Growth in a High-Margin Sector - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Prestige Consumer Healthcare Inc. SEC 10-Q Report - TradingView

Aug 07, 2025
pulisher
Aug 07, 2025

Prestige Consumer misses Q1 revenue estimates, to acquire Pillar5 Pharma - MarketScreener

Aug 07, 2025
pulisher
Aug 07, 2025

Prestige Consumer Healthcare's Fiscal 2026 Q1 Earnings: A Strategic Masterclass in Brand Diversification and Operational Excellence - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Prestige Consumer Healthcare Inc. Reports Fiscal 2026 First Quarter Results - GlobeNewswire

Aug 07, 2025
pulisher
Aug 07, 2025

Prestige Healthcare Reports Mixed Q1 Results, Makes Strategic Eye Care Supplier Acquisition - Stock Titan

Aug 07, 2025
pulisher
Aug 06, 2025

Stay Ahead of the Game With Prestige Consumer Healthcare (PBH) Q1 Earnings: Wall Street's Insights on Key Metrics - Yahoo Finance

Aug 06, 2025
pulisher
Aug 06, 2025

Does Prestige Consumer Healthcare Inc. fit your quant trading modelPredictive AI Engine for Smart Investing - Newser

Aug 06, 2025
pulisher
Aug 06, 2025

Using Python tools to backtest Prestige Consumer Healthcare Inc. strategiesImmediate Entry Point Prediction Strategy - Newser

Aug 06, 2025
pulisher
Aug 05, 2025

Prestige Consumer Healthcare Inc. Flashes Rebound Signal in Oversold ConditionStrong Buy With Technical Confidence Supported - beatles.ru

Aug 05, 2025
pulisher
Aug 05, 2025

Insights Ahead: Prestige Consumer's Quarterly Earnings - 富途牛牛

Aug 05, 2025
pulisher
Aug 05, 2025

TheraTears® Unveils "It's a Science" Marketing Campaign - Yahoo Finance

Aug 05, 2025
pulisher
Aug 04, 2025

Applying sector rotation models to Prestige Consumer Healthcare Inc.Chart-Based Entry Confirmation for Beginners - Newser

Aug 04, 2025
pulisher
Aug 04, 2025

Why Prestige Consumer Healthcare Inc. stock attracts strong analyst attentionHigh Yield Signals with Entry Timing - Newser

Aug 04, 2025
pulisher
Aug 04, 2025

Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Price Is Out Of Tune With Earnings - simplywall.st

Aug 04, 2025
pulisher
Aug 04, 2025

Applying Wyckoff theory to Prestige Consumer Healthcare Inc. stockWeekly High Conviction Trade Setup Analysis - Newser

Aug 04, 2025
pulisher
Aug 04, 2025

Resistance Break Could Fuel Prestige Consumer Healthcare Inc. RallyOptimized Watchlist With Daily Adjustments Launched - metal.it

Aug 04, 2025

Finanzdaten der Prestige Consumer Healthcare Inc-Aktie (PBH)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$28.63
price up icon 4.37%
$17.81
price up icon 2.18%
drug_manufacturers_specialty_generic RDY
$14.26
price up icon 2.52%
$10.41
price up icon 2.87%
$131.62
price up icon 2.12%
$309.72
price up icon 2.76%
Kapitalisierung:     |  Volumen (24h):